Tag: Biotech and Pharma

Novartis beat ​second-quarter profit forecasts and kept its 2026 expectations unchanged on Tuesday, which analysts said ‌signalled it had shifted some costs into the second half.

Tempus ​AI said ‌on Monday ​it ​would acquire ⁠Personalis ​for about $1.5 ​billion to bringing ​its ​cancer test ‌to ⁠the AI-enabled precision ​medicine ​firm’s ⁠oncology portfolio.

Abbott Laboratories had higher revenue in the second quarter, boosted by more sales in its diagnostics business.

Eli Lilly will acquire psychedelic drugmaker AtaiBeckley for $2.8 billion up front, the company said Thursday, as momentum grows for using versions of the drugs as mental health treatments.

UnitedHealth Group on Thursday posted second-quarter earnings that blew past estimates and raised its full-year profit outlook, as the company better manages high medical costs and uses AI to help streamline operations.

Bayer has agreed to sell a minority stake in its contraceptives business to Apollo Global Management in a €3bn deal, as the German pharmaceuticals group seeks to shore up its finances after years of costly US litigation over its Roundup weedkiller.

Shares of AstraZeneca fell as much as 9% after a late-stage clinical trial for a heart disease drug failed to meet its target, with analysts saying the bigger issue may be investors’ trust in the company rather than the loss of a few extra billion in sales.

Crinetics Pharmaceutical stock was surging on Tuesday after Vertex Pharmaceuticals said it had agreed to buy the biotech for $10 billion.

A bipartisan group of U.S. lawmakers has opened national security investigations into whether drugmakers Merck and AbbVie have been involved ​in clinical trials conducted in China that helped fuel the communist country’s military capability, according to letters seen by Reuters.

Shares of French biotech company Abivax soared Tuesday after it released fresh data on its lead drug for bowel disease, clawing back heavy losses from earlier in the month when the same trial had investors questioning the drug’s future.

Σύμφωνα με τα στοιχεία που παρουσιάστηκαν, οι πωλήσεις στο πρώτο εξάμηνο κινούνται με ρυθμό ανόδου της τάξης του 24%, επιβεβαιώνοντας τη δυναμική που έχει αναπτύξει ο όμιλος σε βασικές κατηγορίες προϊόντων και αγορές.

 AbbVie said on Monday it would buy biotech Apogee Therapeutics for $10.9 billion, ​in its largest buyout in more than five years to strengthen its next-gen ‌immunology pipeline.

Britain’s second-largest drugmaker GSK has entered an agreement to acquire U.S.-based drugmaker Nuvalent for $10.6 billion to bolster its oncology pipeline, in what would be its largest acquisition in more than a decade.

Eli Lilly shares jumped in premarket trade on Monday, after a late-stage trial of its next-generation weight-loss drug impressed analysts.

Shares of weight loss drug maker Zealand Pharma plummeted as much as 26% on Monday after new data on its experimental medicine raised concerns over its potential side effects.

Moderna said on Monday it has ​partnered with a global health coalition to develop a potential ‌vaccine against Bundibugyo ebolavirus, the strain linked to the ongoing Ebola outbreak in eastern Democratic Republic of Congo.

Η Lavipharm Α.Ε. ανακοινώνει την ολοκλήρωση της συναλλαγής για την απόκτηση των Αδειών Κυκλοφορίας, των εμπορικών σημάτων και των δικαιωμάτων εμπορικής εκμετάλλευσης και παραγωγής του DUROGESIC® από την Janssen Global Services LLC

Eli Lilly & Co. agreed to buy three vaccine developers for a total of up to about $3.8 billion, marking the drugmaker’s re-entry into the infectious disease space.

Biogen (BIIB.O), will advance its experimental Alzheimer’s drug to late-stage ​development after a mid-stage study showed it slowed mental decline and reduced ‌a key brain protein linked to the disease, although it failed to meet the trial’s main goal.

Telehealth company Hims & Hers’ stock plummeted in early trading Tuesday after posting a first-quarter loss and weak earnings guidance for the year ahead.